In anticipation of our Monday night teleconference on Provenge (see below for registration procedures) I am very happy to report that Dendreon is now detailing plans to move Provenge to earlier stages in the disease’s progress. At the American Society of Clinical Oncology (ASCO) meeting in Chicago which is winding down today, Dendreon unveiled plans [...]
Malecare Cancer Support's Advanced Prostate Cancer Program invites you to our teleconference on Provenge. The Teleconference will begin 6PM EDT, Monday, June 13, 2011. Please register at http://bit.ly/kKuByH Call in number and code will be emailed to you, along with info on how to ask your specific question of our guest. The teleconference will be [...]
There are no right or wrong answers for men with prostate cancer when trying to decide what treatment to have, or even if they want to have treatment. One vital piece of information that is often left out of the equation is the chance of dying from prostate cancer if a man chooses not to [...]
Recent data presented at the 2011 Genitourinary Cancers Symposium supports the growing consensus that intermittent androgen suppression (IADT) is no less effective than continuous androgen suppression at treating men with prostate cancer that recurs after radiotherapy. Lead investigator, Laurence Klotz, MD, chief of urology, Sunnybrook Health Sciences Center, and professor of surgery at the University [...]
Researchers from the Mayo Clinic recently announced results at the American Urological Association (AUA) Annual Meeting from a long-term study that indicates that surgery can improve life expectancy for men with advanced prostate cancer. Their study shows that 80% of men who have advanced prostate cancer and still choose to have surgery survive for at [...]